Chaya,
Merck will be the first to take interest no doubt...
But there will be others...a fair bit of Genentech connections on the PAB Board, now owned by Roche.
Dr Klein was VP Development....Suzy Jones was Head of BD / Partnering...and don't forget where the tech all started - YALE Medical School.
PAB has more international exposure than most ASX Biotech juniors.
Big Pharma will be all over this.
.
Ann: Full size deoxymab PAT-DX3 crosses the blood brain barrier, page-42
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $19.82K | 6.607M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 29828727 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 27089307 | 15 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |